Search This Blog

Tuesday, November 1, 2011

Colombia: Wayuu Gold, Fighting for Access to Fresh Water


In some parts of the world it's as rare as gold — and getting a hold of some, nearly impossible. To one of Colombia's largest indigenous groups indigenous groups, Wayuu, that gold is fresh water. Soon their water will be siphoned from Wayuu lands through new pipes to a nearby town, where the population is not indigenous. As struggles for ethnic rights, such as access to water, are recreated across the country, the community deals with an additional strain on their resources — climate change. Due to a changing climate, water has become even scarcer, leaving the community without a wet season for up to two years at times — before they would at least get this yearly. This documentary tracks one extraordinary woman fighting for her community's very survival.

(Producer: UN Women, 21st Century; Year of Release: 2011)

The Virtual Nurse Will See You Now



A few pointers: A patient interacts with a virtual nurse.
Glenn Kulbako

BIOMEDICINE

The Virtual Nurse Will See You Now

In the hectic world of a hospital, a computer-simulated nurse can be surprisingly comforting.

  • BY EMILY SINGER
Researchers at Northeastern University have developed a virtual nurse and exercise coach that are surprisingly likable and effective—even if they're not quite as affable as the medical hologram on Star Trek. In fact, patients who interacted with a virtual nurse named Elizabeth said they preferred the computer simulation to an actual doctor or nurse because they didn't feel rushed or talked down to.
A recent clinical trial of the technology found that Elizabeth also appears to have a beneficial effect on care. A month after discharge, people who interacted with the virtual nurse were more likely to know their diagnosis and to make a follow-up appointment with their primary-care doctor. The results of the study are currently under review for publication.
"We try to present something that is not just an information exchange but is a social exchange," says Timothy Bickmore, associate professor in Northeastern's College of Computer and Information Science. Bickmore led the research. "It expresses empathy if the patient is having problems, and patients seem to resonate with that."
Bickmore first became interested in working on "virtual agents" after seeing demonstrations of very early interactive animated characters. "I was amazed at how people were instantly mesmerized by them, and how quickly this effect vanished when the characters did something stupid," he says. "I was interested in seeing how they could be engineered to maintain the enchantment over long periods of time and be used for practical purposes beyond entertainment."
He adds that patients with little or no computer experience seem to prefer the virtual person to more standard computer interactions, because it feels more natural.
"Most people get frightened when they hear they are going to get care from a computer, so to hear so clearly that we are not short-changing patients is gratifying," says Joseph Kvedar, a physician and founder and director of the Center for Connected Health at Partners Healthcare. Kvedar has collaborated with Bickmore in the past.
To develop the computer-controlled avatars, researchers first recorded interactions between patients and nurses. They then tried to emulate the nurses' nonverbal communication by endowing the virtual character with hand gestures and facial expressions. (The resulting animation is, however, much simpler than today's sophisticated video games.)
Researchers also add small talk, asking users about local sports teams and the weather, which real nurses and coaches often do to put patients at ease. The verbal interactions are fairly basic; the nurse or trainer has a set repertoire of questions, and users choose from a selection of possible answers. For anything beyond that repertoire, the virtual agent will refer the patient to a human health-care provider.
Adding these apparently simple touches of humanity does appear to influence how people interact with the program. Patients more accurately reported their health information when interacting with the virtual character than they were when filling out a standard electronic questionnaire.
"This was designed from the ground up to be patient-friendly, warm and engaging; it's not necessarily the most lifelike and real-human-looking representation, but through trial and error, they have found the characteristics that resonate with patients," says Steven Simon, chief of general internal medicine at the VA Boston Healthcare System. "I think they are just scratching the surface in terms of how it can best be used, such as in patients with chronic conditions, such as asthma and diabetes." 
Such technologies will become increasingly important with rising health-care costs and an aging population. "We already know we don't have enough health-care providers to go around, and it's only getting worse," says Kvedar. "About 60 percent of the cost of delivering health care comes from human resources, so even if you can train more people, it's not an ideal way to improve costs."
Kvedar worked with Bickmore on a second, home-based trial, in which a virtual coach called Karen encouraged overweight sedentary adults to exercise. Users checked in with Karen three times a week, and she gave them recommendations and listened to their problems. Over 12 weeks, those who talked to the coach were significantly more active than those who simply had an accelerometer to record how much they walked.
"Older adults seem to be really accepting. They like the social aspect of it," says Bickmore. "With the home-based agent, I think they would like to chat with them longer than we let them."
Some users wanted to know more about their virtual coaches, so Bickmore's team experimented with giving the characters a backstory. They found that participants whose virtual coach told them stories in the first person were more likely to log into the system than those who heard the same stories in the third person.
"They had more frequent conversations with the coach when it was being more human, and they did not report feeling more deceived," says Bickmore. He adds that when asked, participants do understand the character is virtual, but they say they sometimes forget. "They say they will feel guilty about not logging in, which means they have formed some kind of emotional bond."
But not everyone responded well to Karen. One of the challenges in broadening the use of this technology will be creating virtual characters that can learn from users and adapt to their preferences.
Bickmore's team is now working on a virtual nurse that would reside in the hospital room. Patients can talk to it about their hospital experience, report pain levels, and ask questions. The researchers are also integrating sensors into the system, to record when the patient is sleeping, for example, or to track when different doctors enter the room.
In a pilot study, patients had an average of 17 conversations with the nurse per day. "When we interviewed them afterward, we found that the agent seemed to be effective at addressing the loneliness you often feel if you're at the hospital by yourself," says Bickmore. 

Test Could Show Which Cancers Will Respond to Chemotherapy



Tumors closer to committing "cellular suicide" are more sensitive to conventional anticancer drugs.

  • BY ERIKA JONIETZ
A laboratory test that evaluates how close cancer cells are to a specific form of cell death could help oncologists predict which patients will benefit from chemotherapy drugs. Researchers tested samples from patients at several hospitals and showed that those whose cancer cells were on the edge of self-destructing responded better to various kinds of chemotherapy.
The test helps explain a long-standing puzzle in oncology. Cancer biology dogma holds that chemotherapy drugs target all rapidly dividing cells, leading to both tumor death and side effects such as hair loss and gastrointestinal distress. But some rapidly dividing tumors, such as pancreatic cancers, tend to be highly resistant to chemotherapy, while some slow-growing cancers, such as chronic myelogenous leukemia, respond well to the drugs.
The new research, led by Anthony Letai, an associate professor at Harvard Medical School and the Dana-Farber Cancer Institute, suggests that regardless of how fast the tumor cells divide, the cancer's likelihood of responding to chemotherapy is correlated with, and perhaps determined by, whether they are approaching a type of cellular suicide known as apoptosis. Apoptosis is a natural process in multicellular organisms, but it is often disrupted in cancerous cells. The study was published online last week in Sciencexpress.
"This is a very important paper," says Peter Sorger, a professor of systems biology at Harvard Medical School, who was not involved in the research. He says identifying patients who might be responsive to chemotherapy is "the key issue in contemporary cancer pharmacology—individualizing treatments so specific drugs are given to patients likely to respond."

Letai and his colleagues tested samples from patients with four kinds of cancer: multiple myeloma, acute myelogenous leukemia, acute lymphocytic leukemia, and ovarian cancer. The process involves taking live tumor cells and exposing them to proteins that promote apoptosis. In cells already on the edge of committing apoptosis, the membranes of energy-producing organelles called mitochondria break down and take up more of a fluorescent dye that the scientists used to monitor the process. This mitochondrial disintegration is one of the first steps in apoptosis. The researchers then followed the patients' response to chemotherapy and found that those whose cells took up the most dye had the best outcomes.
Though the test is more complicated than most cancer diagnostics because it involves handling live cells, Letai believes it could be a practical way to predict which cancer patients will respond to chemotherapy. "In the cancer biology world today, people are looking at genetic biomarkers almost exclusively for trying to understand the response to chemotherapy," he says. "Something like this, a more functional assay, comes out of left field."
Letai's lab is already testing whether the assay could be used in clinical cancer therapy, andEutropics Pharmaceuticals of Cambridge, Massachusetts, which Letai cofounded, has licensed the technology. If clinical trials go well, Letai says, the test might be used for acute myelogenous leukemia in about five years. He hopes that ultimately it will be applicable to most kinds of cancer. Sorger calls the possibility "highly likely."
The researchers also investigated whether treating tumors to move their mitochondria closer to the threshold of apoptosis could boost the efficacy of conventional chemotherapy. They treated a myeloid leukemia cell line with an experimental drug, made by Abbott Labs, that mimics the apoptosis-promoting proteins used in their cell assay. The treated cells became more sensitive to three different chemotherapeutic agents. Abbott and Genentech are collaborating on clinical trials of a related drug, which can be taken orally, to see if it increases the effectiveness of various chemotherapy medicines used for both chronic lymphocytic leukemia and various solid tumors.